ArticleCell death and differentiation2026
GSDME acts as an epigenetic modifier to promote melanoma development via centriole biogenesis regulator PLK4.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Gasdermins have been traditionally recognized for their canonical pore-forming activity in pyroptosis and generally considered as a tumor suppressor due to their low endogenous expression in various types of cancers. However, the pyroptosis-independent role of gasdermins in cellular biological processes remains poorly understood, sparking debates on their actual contribution to cancer pathogenesis. Here, we demonstrate a novel facet of GSDME as an epigenetic modifier that promotes melanoma development through the regulation of the centriole biogenesis regulator PLK4. Unexpectedly, GSDME expression is significantly up-regulated in melanoma, induced by prominent hypo-methylation at its promoter. The deficiency of GSDME prominently suppresses tumor growth and metastasis of melanoma, independent of CD8+ T cell-dependent anti-tumor immunity. Mechanistically, GSDME forms a complex with SMARCA5 and NCL in the nucleus, functioning as an epigenetic regulator, particularly facilitating the transcription of centriole biogenesis regulator PLK4 by increasing its promoter chromatin accessibility. The regulation of PLK4 is greatly implicated in the oncogenic role of GSDME in melanoma. Ultimately, this GSDME-SMARCA5/NCL-PLK4 axis is validated in patients with melanoma and has been proved of promising prognostic potential. Altogether, these results demonstrate that GSDME could be a critical oncogene through its pyroptosis-independent epigenetic regulatory function.
Identifiers
42185629What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.